COVID Vaccines: What FDA Isn’t Talking About Ahead Of Upcoming Advisory Panel

 
• By Sarah Karlin-Smith

From next-generation vaccine technology to safety data and global harmonization, what isn’t in the Vaccines and Related Biological Products Advisory Committee preview documents and on the 26 January meeting agenda may be just as important as what is.  

mrna covid vaccines
What’s not on the 26 January Vaccine Advisory Panel Agenda Is As Notable As What Is • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers